Congenital hyperinsulinism (CHI) is a genetic disorder causing excessive insulin secretion and low blood sugar. It most commonly occurs in newborns and is one of the most frequent causes of recurring hypoglycemia in infants. Treatment of CHI involves high glucose intake and medications such as diazoxide and somatostatin analogs to suppress insulin secretion. However, severe cases may require surgery to partially remove the insulin-producing pancreas. The availability of newer targeted therapies such as exenatide has improved clinical outcomes for children with CHI.
The global Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Key Trends:
The increasing prevalence of genetic disorders associated with CHI is a major driver of market growth. According to recent studies, the prevalence of CHI ranges between 1 in 50,000 to 1 in 216,000 live births. Over the past two decades, rates of CHI diagnoses have increased significantly owing to more advanced genetic testing and improved disease awareness. Another key trend is the rising demand for targeted treatment options with fewer side effects than traditional diazoxide therapy. Pipeline drugs from companies such as Xeris Pharmaceuticals and Crinetics Pharmaceuticals offer promising alternatives for managing varying severities of CHI. With growing burden of genetic diseases, particularly in developed nations, this presents major commercial opportunities in the congested hyperinsulinism treatment market over the coming years.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the medical devices and drugs market require large capital investments and well-established distribution channels. However, small biotech companies are entering the space with novel targeted therapies.
Bargaining power of buyers: The bargaining power of buyers is moderate as the availability of generic drugs increases competition. However, specialty drugs to treat rare conditions have relatively inelastic demand.
Bargaining power of suppliers: The bargaining power of suppliers is low to moderate as raw material inputs are generic and commonly available. However, some biologic drugs depend on limited recombinant proteins manufactured by select companies.
Threat of new substitutes: The threat of new substitutes is high as research focuses on developing improved targeted therapies to treat the root causes of disease better than existing symptomatic treatment options.
Competitive rivalry: The competitive rivalry is high among established pharma companies focused on this therapeutic area given the orphan disease status and potential for high prices and returns on rare disease drugs.
Key Takeaways
The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth over the forecast period supported by the emerging targeted therapies in late stage trials.
Regional analysis: North America currently dominates the market and is expected to continue its dominance over the forecast period supported by growing research activities and availability of advanced healthcare facilities in the US. Europe also has a significant market share supported by increasing government focus on rare disease treatment. However, Asia Pacific is expected to witness fastest growth supported by rising healthcare investments, Western influences, and growing cases of rarer conditions in countries like China and India.
Key players: Key players operating in the congenital hyperinsulinism treatment market are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals.,Crinetics Pharmaceuticals, Inc., AmideBio,LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd. Zealand Pharma’s candidate ZP3143 is among the late stage programs expected to be game changers in the market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.